A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations.

Trial Profile

A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Erdafitinib (Primary) ; Docetaxel; Pembrolizumab; Vinflunine
  • Indications Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms THOR
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 01 May 2018 Status changed from not yet recruiting to recruiting.
    • 11 Mar 2018 Planned number of patients changed from 630 to 631.
    • 11 Mar 2018 Planned End Date changed from 27 Aug 2021 to 27 May 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top